► Resumption of growth in direct sales of Safe Orthopedics
► Safe Medical’s annual turnover up 50%
► Cash position of €0.9m and €8m secured
Éragny-sur-Oise, January 13, 2022 at 5:45 p.m. CET – Safe (FR0013467123 – ALSAF), a company specializing in the design, manufacture and marketing of ready-to-use technologies for back surgery, particularly safe for vertebral fractures treated urgently, today announces its 2021 annual revenue and provides an update on its cash position.
In 2021, the group’s turnover amounted to €4,636k, up 23%, largely explained by the strong growth encountered on Safe medical, up 50%.
Direct sales made by Safe Orthopedics are up +4%, with rising growth quarter after quarter: -18% in Q1, +6% in Q2, +13% in Q3 and +19% in Q4 driven by the acceleration of sales in Germany (429k€, 160%) and the start of marketing in the US (103k€). France experienced a decline of 15% over the year and observed a return to growth of +4% in the last quarter.